Drug Profile
AUTO 3
Alternative Names: Anti-CD19-anti-CD22 CAR T Cell therapy; AUTO 3NG; AUTO3; CD19/22 CAR T cellsLatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator University College London
- Developer Autolus
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 06 Dec 2023 Autolus completes a Phase-I/II development in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy, Monotherapy) in USA and United Kingdom (IV) (NCT03287817) (EudraCT2016-004682-11)
- 06 Jan 2021 AUTO 3 is available for licensing as of 06 Jan 2021. https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-provides-business-outlook-2021-2022
- 07 Dec 2020 Interim efficacy and adverse events data from a phase I/II ALEXANDER trial in diffuse large B cell lymphoma released by Autolus Therapeutics